Liposome Drug Delivery Market Players:
-
Companies Dominating the Liposome Drug Delivery Landscape
Companies in the liposome drug delivery market adopt strategies such as product innovation, focusing on targeted drug delivery, nanotechnology integration, and novel lipid formulations to enhance efficacy. They form strategic partnerships with pharma firms, research institutions, and CDMOs to accelerate development and commercialization. Some of these players include:
- Spectrum Pharmaceuticals, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Gilead Sciences, Inc.
- Celsion Corporation
- Ipsen Pharma
- Pacira Pharmaceuticals, Inc.
- Novartis AG
- CordenPharma International
- FUJIFILM Toyama Chemical Co., Ltd.
- Takeda Pharmaceutical Company Limited
- Johnson & Johnson Services, Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of liposome drug delivery is estimated at USD 6.34 billion.
The global liposome drug delivery market size was around USD 5.88 billion in 2025 and is likely to expand at a CAGR of more than 8.7%, surpassing USD 13.54 billion revenue by 2035.
North America liposome drug delivery market will dominate over 45% share by 2035, attributed to rising cancer rates and increased government R&D initiatives.
Key players in the market include Spectrum Pharmaceuticals, Inc., Gilead Sciences, Inc., Celsion Corporation, Ipsen Pharma, Pacira Pharmaceuticals, Inc., Novartis AG, CordenPharma International, FUJIFILM Toyama Chemical Co., Ltd., Takeda Pharmaceutical Company Limited, Johnson & Johnson Services, Inc.
